Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 branebrutinib placebo-controlled study in primary Sjögren's syndrome, rheumatoid arthritis, and systemic lupus erythematosus
NL-OMON52687Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of branebrutinib and abatacept in primary Sjögren's syndrome, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Composite Week 24 response, ACR50 at Week 12 and 2 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
branebrutinibabatacept
03
Conditions
primary Sjögren's syndromerheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON52687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52687.